JP2005512997A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512997A5
JP2005512997A5 JP2003541821A JP2003541821A JP2005512997A5 JP 2005512997 A5 JP2005512997 A5 JP 2005512997A5 JP 2003541821 A JP2003541821 A JP 2003541821A JP 2003541821 A JP2003541821 A JP 2003541821A JP 2005512997 A5 JP2005512997 A5 JP 2005512997A5
Authority
JP
Japan
Prior art keywords
liquid
pharmaceutically acceptable
active ingredient
acceptable excipient
pharmaceutical tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512997A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2002/000695 external-priority patent/WO2003039530A1/en
Publication of JP2005512997A publication Critical patent/JP2005512997A/ja
Publication of JP2005512997A5 publication Critical patent/JP2005512997A5/ja
Pending legal-status Critical Current

Links

JP2003541821A 2001-11-07 2002-11-01 タムスロシン錠 Pending JP2005512997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33105501P 2001-11-07 2001-11-07
PCT/NL2002/000695 WO2003039530A1 (en) 2001-11-07 2002-11-01 Tamsulosin tablets

Publications (2)

Publication Number Publication Date
JP2005512997A JP2005512997A (ja) 2005-05-12
JP2005512997A5 true JP2005512997A5 (enExample) 2006-01-05

Family

ID=23292437

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003541821A Pending JP2005512997A (ja) 2001-11-07 2002-11-01 タムスロシン錠
JP2003541822A Withdrawn JP2005511591A (ja) 2001-11-07 2002-11-06 放出調節型タムスロシン錠
JP2010232415A Expired - Lifetime JP5536610B2 (ja) 2001-11-07 2010-10-15 放出調節型タムスロシン錠

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2003541822A Withdrawn JP2005511591A (ja) 2001-11-07 2002-11-06 放出調節型タムスロシン錠
JP2010232415A Expired - Lifetime JP5536610B2 (ja) 2001-11-07 2010-10-15 放出調節型タムスロシン錠

Country Status (21)

Country Link
US (2) US20030147955A1 (enExample)
EP (3) EP1443917B1 (enExample)
JP (3) JP2005512997A (enExample)
CN (3) CN1298317C (enExample)
AT (3) ATE321544T1 (enExample)
AU (1) AU2002301845B2 (enExample)
CA (2) CA2465110A1 (enExample)
CZ (3) CZ16809U1 (enExample)
DE (4) DE20220415U1 (enExample)
DK (3) DK1443917T3 (enExample)
ES (2) ES2256544T3 (enExample)
HU (2) HUP0401978A3 (enExample)
IL (4) IL161491A0 (enExample)
NL (2) NL1021822C2 (enExample)
NO (2) NO340960B1 (enExample)
NZ (2) NZ532589A (enExample)
PT (2) PT1443917E (enExample)
RU (2) RU2311903C2 (enExample)
SI (2) SI1443917T1 (enExample)
WO (2) WO2003039530A1 (enExample)
ZA (2) ZA200403281B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
IN192381B (enExample) * 2002-12-20 2004-04-10 Ranbaxy Lab
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
EA200600066A1 (ru) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
JP2007507491A (ja) * 2003-09-29 2007-03-29 シージェー コーポレーション 徐放性製剤
KR100762846B1 (ko) * 2003-09-29 2007-10-04 씨제이 주식회사 서방성 제제
JP2005104914A (ja) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162737A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US8128958B2 (en) 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21702A (en) * 2004-01-29 2005-08-31 Lek Farmacevtska Druzba Dd Preparation of amorphous form of tamsulosin
JP4603803B2 (ja) * 2004-01-30 2010-12-22 大洋薬品工業株式会社 放出制御医薬組成物およびこれを用いる製剤
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
RU2390354C2 (ru) * 2004-12-27 2010-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
CN1895241B (zh) * 2005-07-12 2010-05-12 可隆制药株式会社 盐酸坦洛新的口服长效性小药丸组成物及其制造方法
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR20070044911A (ko) * 2005-10-26 2007-05-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
WO2007131804A1 (en) * 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2042169A1 (en) * 2007-09-26 2009-04-01 LEK Pharmaceuticals D.D. Controlled release tamsulosin hydrochloride tablets and a process of making them
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
JP5787881B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
WO2012161240A1 (ja) * 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
CN102579392A (zh) * 2012-03-30 2012-07-18 重庆科瑞制药(集团)有限公司 一种含有盐酸坦索罗辛的缓释制剂及其制备方法
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
CA3078568A1 (en) 2017-10-12 2019-04-18 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
SU1440327A3 (ru) * 1980-07-03 1988-11-23 Тейт Энд Лайл Паблик Лимитед Компани (Фирма) Способ получени таблетированной формы препарата
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2147866A1 (en) * 1992-11-04 1994-05-11 Nancy M. Gray Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
AU7085194A (en) * 1993-07-14 1995-02-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for urination disorder accompanying prostatic hypertrophy
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
JP4221068B2 (ja) * 1997-12-17 2009-02-12 興和創薬株式会社 テオフィリン徐放性錠剤及びその製造方法
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
JP2000080032A (ja) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd 排出障害治療剤
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MX339071B (es) * 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
BR0009327A (pt) * 1999-08-09 2002-01-22 Yamanouchi Pharma Co Ltd Composição farmacêutica para a terapia de sintomas do trato urinário inferior
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
CN1473035B (zh) * 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets

Similar Documents

Publication Publication Date Title
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
FI5842U1 (fi) Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita
JP2005520796A5 (enExample)
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
PL378270A1 (pl) Preparat farmaceutyczny zawierający nierozpuszczalny środek czynny
PL400027A1 (pl) Wieloelementowa farmaceutyczna postac dawkowania i sposób jej wytwarzania
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
JP2021535107A5 (enExample)
ATE541562T1 (de) Ibuprofen-suspension
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
DE50105771D1 (de) Ibuprofen-wirkstoffzubereitung
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
NO20060445L (no) Fast farmasoytisk preparat omfattende amisulprid
JP2002542248A5 (enExample)
JP2005511619A5 (enExample)
HRP20050371A2 (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
BR0112847A (pt) Uso de uma forma de dosagem sólida
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
WO2005051350A3 (en) Water dispersible tablet
JP2008515980A5 (enExample)
ZA200506992B (en) Fibrate tablet and method for the production thereof
WO2005004836A3 (en) Saquinavir mesylate oral dosage form